Actively Recruiting
Evaluating Canakinumab to Reduce Vascular Inflammation in Coronary Artery Disease with and without TET2 Mutations
Led by Massachusetts General Hospital · Updated on 2026-10-15
120
Participants Needed
1
Research Sites
65 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of canakinumab, an antibody that targets interleukin-1B, on vascular inflammation in people with coronary artery disease. This study includes individuals with and without TET2 gene mutations and aims to assess whether canakinumab can reduce inflammation in blood vessels. Half of the participants will have TET2 mutations, and the study is designed as a randomized, double-blind, placebo-controlled trial. Participants will be randomly assigned to receive either canakinumab at a dose of 150 mg or a placebo injection every three months for four doses. The study involves imaging tests including coronary CT angiography for all participants and a subset will undergo additional SPECT imaging to measure macrophage-specific vascular inflammation. Injection and safety visits occur at weeks 0, 12, 24, and 36, with repeat imaging at week 48 and final assessments at week 60. Throughout the study, participants will attend scheduled visits for injections, safety monitoring, and imaging assessments to track changes in vascular inflammation and TET2 mutation levels. The main outcome measured is the change in fat attenuation index by coronary CT angiography between baseline and week 48. Secondary outcomes include changes in TET2 variant allele fraction. Safety evaluations continue through the final visit, and the entire participation period extends up to 60 weeks.
CONDITIONS
Brief Title
Effects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis
Research Team
M
Michael C Honigberg, MD MPP
M
Mabel Toribio, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here